欢迎访问《中国真菌学杂志》杂志官方网站,今天是 分享到:

中国真菌学杂志 2013, Vol. 8  Issue (2): 105-108.

真菌病治疗 上一篇    下一篇

不同方法口服特比萘芬片治疗趾甲甲真菌病的疗效观察

沈毅   

  1. 湖北省直属机关医院皮肤科, 武汉 420071
  • 收稿日期:2012-10-21 出版日期:2013-04-28 发布日期:2013-04-28
  • 作者简介:沈毅,男 (汉族),本科,副主任医师.E-mail:259912798@qq.com

Observation on therapeutic effect of terbinafine taken orally with different methods in the treatment of toenail onychomycosis

SHEN Yi   

  1. Hubei Subordinate Hospital for the Provincial Govermment, Wuhan 430071, China
  • Received:2012-10-21 Online:2013-04-28 Published:2013-04-28

摘要: 目的 评价不同方法口服特比萘芬片治疗趾甲甲真菌病的疗效。方法 将入选患者随机分成两组,A组口服特比萘芬片0.25 g/d连续12周,B组前4周0.25 g/d,第5周开始隔天服0.25 g至16周,分别于治疗开始前、16周及26周对观察指标进行记录、分析。结果 共入选1 001例,其中A组512例,16周、26周临床有效率分别是83.01%、95.31%,B组489例,16周、26周临床有效率分别是81.12%、93.86%,两组对应观察期有效率经χ2检验,差异无统计学意义,26周时有效率比16周有进一步提高。结论 4周后隔日服药疗法在减少服用14片特比萘芬片的情况下可以达到与常规治疗组近似的疗效,患者依从性较高,特比萘芬片治疗甲真菌病具有明显的后效应。

关键词: 甲真菌病, 特比萘芬, 依从性

Abstract: Objective The curative effect of terbinafine taken orally with different methods in the treatment of toenail onychomycosis was evaluated.Methods Based on group controlled, group A took oral terbinafine tablet 0.25 g/d for consecutive 12 weeks, group B took oral terbinafine tablet 0.25 g/d for the first 4 weeks, and then alternate-day dosing 0.25 g from the 5th week to the 16th week, recording and analyzing assessment at the 16th week and the 26th week respectively.Results 1 001 cases were validated.Group A got 512 cases which the clinical efficiency was 83.01%, 95.31% respectively; group B got 489 cases which the clinical efficiency was 81.12%, 93.86% respectively.Conclusion Two groups' corresponding period of observation efficiency by the chi-square test was difference with no statistically significant. In reducing dosage for 14 tablets can achieve similar efficacy, with it can improve the compliance of patient. Comparing the result of 26th week with the 16th week, curative effect further improved, it indicated that terbinafine tablet treatment to onychomycosis got significant after-effect.

Key words: onychomycosis, terbinafine, compliance

中图分类号: